Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
about
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitorsMelanoma: From Incurable Beast to a Curable Bet. The Success of ImmunotherapyTherapeutic cancer vaccines: past, present, and futureImmune modulation of the tumor microenvironment for enhancing cancer immunotherapyStructure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicityThe blockade of immune checkpoints in cancer immunotherapyCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyUpdate on immune checkpoint inhibitors in gynecological cancersAnti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapyTherapeutic cancer vaccines and combination immunotherapies involving vaccinationIBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CAPD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesCurrent status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical modelFeatures of responding T cells in cancer and chronic infection.Current status of cancer immunotherapyVISTA Regulates the Development of Protective Antitumor Immunity.Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanomaImmune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escapeExpression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerEvaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma modelOpportunities and challenges in the development of experimental drug combinations for cancer.Cancer immunotherapy comes of ageBeyond adjuvants: immunomodulation strategies to enhance T cell immunityDendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.Therapeutic cancer vaccines: current status and moving forward.Whole cell vaccines--past progress and future strategies.Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patientsPreclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyWhole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma.Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy.The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppressionTherapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway.
P2860
Q26778793-BEB22D7F-7FEF-45F4-85E9-4D4D78AA9B2AQ26798404-A1F55976-B012-4774-A672-A1ED12FB7748Q26863283-564DD13F-C399-4CAD-914A-C1060CE069B7Q27002646-95F8C37E-547C-4743-A383-DE52AECB537AQ27680213-E7733628-755A-421B-96BD-2A808A627288Q27860852-BC033562-FBD2-4733-91B1-B4AC611FDF08Q28066199-0A5B3D18-82E4-4316-AA17-3A67ECF690E0Q28076497-49DEB4FB-79FB-4A29-A39E-2FD805FDC8D6Q28235277-E8C90D82-D3A1-4FCC-8FA3-7BD303DBD85AQ28397609-B0E43CB1-2D5A-428C-B998-682D524BDC0BQ28660580-EDF3C275-1ACC-4117-AD08-BEB007D030CFQ29619686-A31C5EDA-91FE-4512-AD17-FBEBFE1E68F6Q29620051-1D8B140F-FE50-4D3A-9AF6-367641EFE05DQ30412300-72793ACA-A04F-4FDA-AC2E-2DB520932A82Q30846001-48266566-FE71-4D3C-933D-E71422288A69Q33728672-314E9747-C5C6-4221-9B11-DD45CD51510EQ33941340-FEC2BEF8-211F-4337-817B-DB8014814F7DQ33955720-797D395F-2150-4FF6-8095-374EE59DD5F1Q33978040-0B43BBC6-63FE-44CA-B859-AB58D03D7639Q34034408-6E2D7522-82F1-417A-8E48-205D74BBD15DQ34241893-F18FF266-FB72-4301-B1AB-957699F64E6CQ34270064-C40BF9A8-E3E9-4EC4-ACE0-A9A59D440036Q34362516-8197BE54-C340-4F5E-A0E1-30EE5D489947Q34548226-FEE38F85-751E-42D4-A0E6-225480F5E9A8Q34644359-CB541165-7E36-4F39-9338-A63544C9B0A4Q35516545-2272CABF-11D7-4648-BF3E-936CA3C17D01Q35555293-23C0FDD8-DE13-44F6-81BD-3F0F2A982040Q35666338-55B71A3E-98B3-4A7B-99C5-A6AE2C3B3BBCQ35666506-393047E8-F268-44AA-BFDC-72E4E68274FEQ35821826-D5695240-D66F-4CFD-8377-ADCBFE4EB66BQ35894347-B5B2A205-8DEE-4F46-9476-555A3950E8CCQ35975381-391A92B3-CE78-4862-B28C-780373EF7ECFQ36057487-DDD95755-2C36-419A-B8F6-E3158068A132Q36127709-C9BC6312-39A6-4B76-A85B-D7798258CC3FQ36193892-9F287F14-3765-49EF-97FD-C9DD1D74ADE6Q36821133-640C05DC-FE57-4AC3-83C0-397DB731A26FQ37253328-F33B1E77-9655-43C5-A730-4D02BFE81596Q37309250-C9244AAE-9D1D-4A91-B938-3C1A7854F0DCQ37558139-4D051702-5D15-49C6-B300-1C659D286ECBQ37686978-9265A050-3888-414F-9D7C-43AFA3394B16
P2860
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Anti-programmed death-1 synerg ...... mice with established tumors.
@en
Anti-programmed death-1 synerg ...... mice with established tumors.
@nl
type
label
Anti-programmed death-1 synerg ...... mice with established tumors.
@en
Anti-programmed death-1 synerg ...... mice with established tumors.
@nl
prefLabel
Anti-programmed death-1 synerg ...... mice with established tumors.
@en
Anti-programmed death-1 synerg ...... mice with established tumors.
@nl
P2093
P1476
Anti-programmed death-1 synerg ...... mice with established tumors.
@en
P2093
Alan Korman
Changyu Wang
Karin Jooss
Melinda VanRoey
Tseng-hui Timothy Chen
P304
P356
10.1158/1078-0432.CCR-08-1825
P407
P577
2009-02-10T00:00:00Z